Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure (REaCH)


Aspirus Heart and Vascular Institute-Research and Education

Status and phase

Phase 3


Renal Insufficiency
Congestive Heart Failure


Drug: furosemide
Drug: furosemide and hypertonic saline solution

Study type


Funder types




Details and patient eligibility


The purpose of this study is to compare high dose furosemide in combination with low volume hypertonic saline solution (2.4%) with intermittent pulse dose furosemide in patients with pre treatment kidney function impairment. The hypothesis is that it will provide effective diuretic response and have a beneficial effect on preservation of renal function as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).

Full description

Currently, congestive heart failure (CHF) is the fastest growing heart-related diagnosis in North America, with the chance of a person experiencing it during their lifetime around 20%. In patients with CHF, acute decompensation requiring hospitalizations are common. Patients with renal insufficiency are more susceptible to worsening of renal function or overt renal failure in relation to an episode of decompensated heart failure. Thus, there is a great need for treatment to help patients with renal dysfunction that can simultaneously protect them from further renal deterioration. Preliminary evidence indicates that hypertonic saline solution (HSS) combined with high dose loop diuretics may improve the prognosis for patients with CHF. In two separate studies, this treatment was found to alleviate symptoms of CHF, and significantly reduce hospital length of stay, as well as reduce morbidity and mortality subsequent to hospital stay. So far, available studies have demonstrated that renal function is not compromised when using HSS and high dose furosemide as a treatment for CHF. Preliminary data from our institution suggests that low volume HSS combined with high dose furosemide may be beneficial for patients with renal insufficiency. Hypothesis: High dose furosemide in combination with low volume HSS provides effective diuretic response and has a beneficial effect on preservation of renal function while in hospital as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).


50 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

Uncompensated CHF Framingham Criteria for HF 2 Major or 1 Major 2 minor Major criteria: Paroxysmal nocturnal dyspnea Neck vein distention Rales Radiographic cardiomegaly (increasing heart size on chest radiography) Acute pulmonary edema S3 gallop Increased central venous pressure (>16 cm H2O at right atrium) Hepatojugular reflux Weight loss > 4.5 kg in 5 days in response to treatment Minor criteria: Bilateral ankle edema Nocturnal cough Dyspnea on ordinary exertion Hepatomegaly Pleural effusion Decrease in vital capacity by one third from maximum recorded Tachycardia (heart rate>120 beats/min.) No Ejection Fraction Inclusion Criteria GFR £ 60 mL/min GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American) (conventional units). Informed consent

Exclusion criteria

Patients with Acute Coronary Syndrome Post -op patients within 90 days of previous surgery Patients currently on dialysis Hospice patients Patients < 18 years of age.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

50 participants in 2 patient groups

Furosemide with Hypertonic Saline
Experimental group
Furosemide with 150 mL of 2.4% NaCl
Drug: furosemide and hypertonic saline solution
Pulse Furosemide
Active Comparator group
80-160 mg furosemide (Given over 5 min IV twice a day)
Drug: furosemide

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems